S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
NASDAQ:RPHM

Reneo Pharmaceuticals (RPHM) Stock Forecast, Price & News

$7.58
+0.49 (+6.91%)
(As of 05:12 PM ET)
Compare
Today's Range
$7.00
$7.97
50-Day Range
$5.44
$8.03
52-Week Range
$1.79
$11.30
Volume
104,212 shs
Average Volume
116,214 shs
Market Capitalization
$256.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00

Reneo Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
282.7% Upside
$30.00 Price Target
Short Interest
Bearish
10.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.43mentions of Reneo Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$808,125 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

710th out of 968 stocks

Pharmaceutical Preparations Industry

321st out of 445 stocks


RPHM stock logo

About Reneo Pharmaceuticals (NASDAQ:RPHM) Stock

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

RPHM Price History

RPHM Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
H.C. Wainwright Keeps Their Buy Rating on Reneo Pharmaceuticals (RPHM)
Overlooked AI Stock Gets Urgent "Buy"
We issued our first "Buy" rating on Apple when it traded at the equivalent of 56 cents per share. It's up 32,571% since. And while Nvidia is up 3x this year… We called it back in 2011. And it has surged 97x (9,624% to be exact) since then. Now, our Weiss Ratings has issued a "Buy" on a stock that's leading the AI revolution in one of the most profitable industries.
RPHM Reneo Pharmaceuticals, Inc.
See More Headlines
Receive RPHM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reneo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RPHM Company Calendar

Last Earnings
8/10/2023
Today
9/22/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RPHM
Fax
N/A
Employees
51
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$30.00
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+282.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-51,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.08 per share

Miscellaneous

Free Float
27,751,000
Market Cap
$264.99 million
Optionable
Not Optionable
Beta
1.14
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Michael G. Grey (Age 70)
    Founder & Exec. Chairman
    Comp: $100k
  • Mr. Gregory J. FlesherMr. Gregory J. Flesher (Age 53)
    Pres, CEO & Director
    Comp: $800.45k
  • Mr. Michael P. CruseMr. Michael P. Cruse (Age 51)
    Chief Operating Officer
    Comp: $535.47k
  • Ms. Ashley F. Hall J.D. (Age 51)
    Chief Devel. Officer
    Comp: $661.55k
  • Ms. Jennifer P. Lam
    Sr. VP of Fin., Principal Financial & Accounting Officer
  • Dr. Alejandro Dorenbaum M.D. (Age 62)
    Chief Medical Officer
  • Ms. Lynn Purkins Ph.D.
    Sr. VP of Clinical Operations













RPHM Stock - Frequently Asked Questions

Should I buy or sell Reneo Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Reneo Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RPHM shares.
View RPHM analyst ratings
or view top-rated stocks.

What is Reneo Pharmaceuticals' stock price forecast for 2023?

2 Wall Street analysts have issued 12-month price targets for Reneo Pharmaceuticals' stock. Their RPHM share price forecasts range from $30.00 to $30.00. On average, they anticipate the company's stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 282.7% from the stock's current price.
View analysts price targets for RPHM
or view top-rated stocks among Wall Street analysts.

How have RPHM shares performed in 2023?

Reneo Pharmaceuticals' stock was trading at $2.33 at the beginning of 2023. Since then, RPHM shares have increased by 236.5% and is now trading at $7.84.
View the best growth stocks for 2023 here
.

When is Reneo Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our RPHM earnings forecast
.

How were Reneo Pharmaceuticals' earnings last quarter?

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) announced its earnings results on Thursday, August, 10th. The company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by $0.10.

When did Reneo Pharmaceuticals IPO?

(RPHM) raised $101 million in an initial public offering (IPO) on Friday, April 9th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

What is Reneo Pharmaceuticals' stock symbol?

Reneo Pharmaceuticals trades on the NASDAQ under the ticker symbol "RPHM."

Who are Reneo Pharmaceuticals' major shareholders?

Reneo Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Carlyle Group Inc. (8.02%), Eventide Asset Management LLC (5.20%), Franklin Resources Inc. (4.00%), Great Point Partners LLC (3.22%), ExodusPoint Capital Management LP (1.65%) and BlackRock Inc. (1.36%). Insiders that own company stock include Ashley Hall, Bali Muralidhar, Gregory J Flesher, Holdings A/S Novo, Michael Cruse, Niall O'donnell, Venture Fund Iii L Rivervest and Vineet R Jindal.
View institutional ownership trends
.

How do I buy shares of Reneo Pharmaceuticals?

Shares of RPHM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Reneo Pharmaceuticals' stock price today?

One share of RPHM stock can currently be purchased for approximately $7.84.

How much money does Reneo Pharmaceuticals make?

Reneo Pharmaceuticals (NASDAQ:RPHM) has a market capitalization of $264.99 million. The company earns $-51,960,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis.

How can I contact Reneo Pharmaceuticals?

The official website for the company is reneopharma.com. The company can be reached via phone at 858-283-0280 or via email at investors@reneopharma.com.

This page (NASDAQ:RPHM) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -